Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Complete Genomics, Soon to Be a BGI Subsidiary, Wins Partial Victory in Illumina Suit

publication date: Oct 19, 2012
Complete Genomics, the California sequencing company, gained a partial victory in Illumina’s patent suit against the company. The judge rejected Claim 1 of the suit, ruling that prior art shows Illumina’s technology was not novel. In September, BGI, the giant sequencing company headquartered in Shenzhen, announced it would buy Complete Genomics for $127 million. More details....

Stock Symbols: (NSDQ: GNOM) (NSDQ: ILMN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital